Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

Keyphrases

• Natalizumab 100%
• Progressive multifocal Leukoencephalopathy 100%
• Multiple Sclerosis 100%
• Immune Reconstitution 18%
• Plasma Exchange 18%
• JC Virus 18%
• Seizure 9%
• Improved Outcomes 9%
• Contrast Enhancement 9%
• Treatment Duration 9%
• Clinical Events 9%
• Multiple Sclerosis Treatment 9%
• Disease-modifying Therapy 9%
• Clinical Diagnosis 9%
• Symptom Onset 9%
• HIV-associated 9%
• Future Therapeutics 9%
• Enlargement 9%
• Predictive Marker 9%
• Patients at Risk 9%
• Motor Performance 9%
• Exposure Time 9%
• Presenting Symptoms 9%
• Rare Occurrence 9%
• PCR Test 9%
• Cognition Performance 9%

Neuroscience

• Natalizumab 100%
• Progressive Multifocal Leukoencephalopathy 100%
• Multiple Sclerosis 100%
• Magnetic Resonance Imaging 27%
• JC Virus 18%
• Blood Plasma 18%
• Immunosuppressant 9%
• Human Immunodeficiency Virus 9%
• Treatment of Multiple Sclerosis 9%
• Vigilance 9%

Pharmacology, Toxicology and Pharmaceutical Science

• Multiple Sclerosis 100%
• Natalizumab 100%
• Progressive Multifocal Leukoencephalopathy 100%
• JC Virus 18%
• Immune Reconstitution Inflammatory Syndrome 18%
• Immunosuppressive Agent 9%
• HIV 9%
• Syndrome 9%
• Diseases 9%